- Home
- NCTY vs MOLN Comparison
NCTY vs MOLN Comparison
Compare NCTY & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- MOLN
- Stock Information
- Founded
- NCTY 1999
- MOLN 2004
- Country
- NCTY China
- MOLN Switzerland
- Employees
- NCTY N/A
- MOLN N/A
- Industry
- NCTY Business Services
- MOLN
- Sector
- NCTY Consumer Discretionary
- MOLN
- Exchange
- NCTY Nasdaq
- MOLN Nasdaq
- Market Cap
- NCTY 121.2M
- MOLN 142.6M
- IPO Year
- NCTY 2004
- MOLN 2021
- Fundamental
- Price
- NCTY $10.32
- MOLN $3.58
- Analyst Decision
- NCTY
- MOLN Hold
- Analyst Count
- NCTY 0
- MOLN 1
- Target Price
- NCTY N/A
- MOLN $4.00
- AVG Volume (30 Days)
- NCTY 48.4K
- MOLN 5.0K
- Earning Date
- NCTY 01-01-0001
- MOLN 11-05-2025
- Dividend Yield
- NCTY N/A
- MOLN N/A
- EPS Growth
- NCTY N/A
- MOLN N/A
- EPS
- NCTY N/A
- MOLN N/A
- Revenue
- NCTY $15,305,175.00
- MOLN $856,302.00
- Revenue This Year
- NCTY N/A
- MOLN N/A
- Revenue Next Year
- NCTY N/A
- MOLN $1,000.00
- P/E Ratio
- NCTY N/A
- MOLN N/A
- Revenue Growth
- NCTY N/A
- MOLN N/A
- 52 Week Low
- NCTY $6.28
- MOLN $3.36
- 52 Week High
- NCTY $20.59
- MOLN $7.60
- Technical
- Relative Strength Index (RSI)
- NCTY 64.22
- MOLN 46.94
- Support Level
- NCTY $8.60
- MOLN $3.54
- Resistance Level
- NCTY $9.39
- MOLN $3.86
- Average True Range (ATR)
- NCTY 0.67
- MOLN 0.21
- MACD
- NCTY 0.22
- MOLN -0.01
- Stochastic Oscillator
- NCTY 85.53
- MOLN 8.27
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China, Asia/Eastern Europe, and North America. Its segments are: Crypto mining business, and Other, out of which Crypto mining business derives maximum revenue.
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.